Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC1679-0001 in Healthy Participants and Participants With T2DM
NCT07570992Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NNC1679-0001 with Placebo (2 arms). Primary endpoint: Number of Treatment-Emergent Adverse Events at week 34. Started May 2026; status: recruiting.
02
Drugs
NNC16790001
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07570992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570992.